152
Participants
Start Date
June 15, 2022
Primary Completion Date
October 31, 2026
Study Completion Date
April 30, 2027
ADG126
ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.
Pembrolizumab (KEYTRUDA®)
Pembrolizumab (KEYTRUDA®) is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).
Standard of Care (Trifluridine/Tipiracil-Bevacizumab)
The standard of care therapies will include Trifluridine/Tipiracil-Bevacizumab, approved for treating metastatic colorectal cancer (CRC)and various solid tumors.
Standard of care (Fruquintinib)
The standard of care therapy, Fruquintinib, is approved for treating metastatic colorectal cancer (CRC) and various solid tumors.
RECRUITING
Severance Hospital Yonsei University Health System, Seoul
RECRUITING
CHA Bundang Medical Center, CHA university, Seongnam
RECRUITING
The Catholic University of Korea Street. Vincent Hospital, Suwon
RECRUITING
Chungbuk National University Hospital, Cheongju-si
RECRUITING
Florida cancer specialist/Sarah Cannon Research Institute, Sarasota
RECRUITING
Keimyung University Dongsan Hospital, Daegu
RECRUITING
Dong -A University Hospital, Seogu
RECRUITING
Honor Health Research Institute, Scottsdale
RECRUITING
City of Hope National Medical Center, Duarte
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
SunYat-Sen University Cancer Center, Guangzhou
RECRUITING
Hong Kong Humanity & Health Clinical Trial Center, Hong Kong
RECRUITING
Prince of Wales Hospital, Hong Kong
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
KangBuk Samsung Hospital, Seoul
RECRUITING
Asan Medical Center, Seoul
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Adagene Inc
INDUSTRY